These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33811377)

  • 1. Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired-hepatic function.
    Wicha WW; Marbury TC; Dowell JA; Crandon JL; Leister C; Ermer J; Gelone SP
    Pharmacotherapy; 2021 May; 41(5):457-462. PubMed ID: 33811377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of lefamulin after single intravenous dose administration in subjects with impaired renal function and those requiring hemodialysis.
    Wicha WW; Marbury TC; Dowell JA; Crandon JL; Leister C; Ermer J; Gelone SP
    Pharmacotherapy; 2021 May; 41(5):451-456. PubMed ID: 33797776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA
    Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
    File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ
    BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing.
    Wicha WW; Prince WT; Lell C; Heilmayer W; Gelone SP
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii19-iii26. PubMed ID: 30949704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
    File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB
    Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods.
    Zhang L; Wicha WW; Bhavnani SM; Rubino CM
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii27-iii34. PubMed ID: 30949708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lefamulin: The First Systemic Pleuromutilin Antibiotic.
    Chahine EB; Sucher AJ
    Ann Pharmacother; 2020 Dec; 54(12):1203-1214. PubMed ID: 32493034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin.
    Rodvold KA
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii2-iii4. PubMed ID: 30949709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis.
    Sawicki GS; Wicha WW; Hiley TS; Close NC; Gelone SP; Guico-Pabia CJ
    Clin Ther; 2024 Feb; 46(2):96-103. PubMed ID: 38195348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of lefamulin in the treatment of community-acquired pneumonia.
    Perry W; Golan Y
    Future Microbiol; 2019 Jul; 14():927-939. PubMed ID: 31333062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.
    Tang HJ; Wang JH; Lai CC
    Medicine (Baltimore); 2020 Jul; 99(29):e21223. PubMed ID: 32702892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review of Newly Approved Antibiotic Treatment for Community-Acquired Bacterial Pneumonia: Lefamulin.
    Wang H; Charles CV
    Sr Care Pharm; 2020 Aug; 35(8):349-354. PubMed ID: 32718391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.
    Veve MP; Wagner JL
    Pharmacotherapy; 2018 Sep; 38(9):935-946. PubMed ID: 30019769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
    Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of lefamulin for the treatment of community acquired bacterial pneumonia.
    Falcó V; Burgos J; Almirante B
    Expert Opin Pharmacother; 2020 Apr; 21(6):629-636. PubMed ID: 31958020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
    Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
    Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
    Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
    Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia.
    Lee YR; Jacobs KL
    Drugs; 2019 Nov; 79(17):1867-1876. PubMed ID: 31705486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia.
    Watkins RR; File TM
    Clin Infect Dis; 2020 Dec; 71(10):2757-2762. PubMed ID: 32221520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.